{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"9"},{"groupId":"BG007","value":"31"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"153"},{"groupId":"BG010","value":"18"},{"groupId":"BG011","value":"5"},{"groupId":"BG012","value":"20"},{"groupId":"BG013","value":"21"},{"groupId":"BG014","value":"20"},{"groupId":"BG015","value":"10"},{"groupId":"BG016","value":"11"},{"groupId":"BG017","value":"336"}],"units":"Participants"}],"groups":[{"description":"Participants with AML or MDS received single agent of FT-2102 100 mg orally QD in 28-day cycles until MTD or MED achieved.","id":"BG000","title":"Phase 1: FT-2102 100mg QD (Single Agent; Dose Escalation)"},{"description":"Participants with AML or MDS received single agent of FT-2102 150 mg orally QD in 28-day cycles until MTD or MED achieved.","id":"BG001","title":"Phase 1: FT-2102 150mg QD (Single Agent; Dose Escalation)"},{"description":"Participants with AML or MDS received single agent of FT-2102 150 mg orally BID in 28-day cycles until MTD or MED achieved.","id":"BG002","title":"Phase 1: FT-2102 150mg BID (Single Agent; Dose Escalation)"},{"description":"Participants with AML or MDS received single agent of FT-2102 300 mg orally QD in 28-day cycles until MTD or MED achieved.","id":"BG003","title":"Phase 1: FT-2102 300mg QD (Single Agent; Dose Escalation)"},{"description":"Participants with AML or MDS received combination therapy (FT-2102 150 mg QD and azacitidine administered at the dose of 75 mg/m\\^2 for 7 days IV/SC per every 28-day cycle) until treatment discontinuation.","id":"BG004","title":"Phase 1: FT-2102 150mg QD+Azacitidine (Combination Therapy; Dose Escalation)"},{"description":"Participants with AML or MDS received combination therapy (FT-2102 150 mg BID and azacitidine administered at the dose of 75 mg/m\\^2 for 7 days IV/SC per every 28-day cycle) until treatment discontinuation.","id":"BG005","title":"Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Escalation)"},{"description":"Participants with AML or MDS received single agent of FT-2102 150 mg orally BID in 28-day cycles until MTD or MED achieved.","id":"BG006","title":"Phase 1: FT-2102 150mg BID (Single Agent; Dose Expansion)"},{"description":"Participants with AML or MDS received combination therapy (FT-2102 150 mg BID and azacitidine administered at the dose of 75 mg/m\\^2 for 7 days IV/SC per every 28-day cycle) until treatment discontinuation.","id":"BG007","title":"Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Expansion)"},{"description":"Participants with AML harboring IDH1 mutation received FT-2102 150 mg BID in combination with LDAC administered at the dose of 20 mg BID SC for 10 days every 28-day cycle until treatment discontinuation.","id":"BG008","title":"Phase 1: FT-2102 150mg BID+ Cytarabine (Combination Therapy; Dose Expansion)"},{"description":"Participants with R/R AML received single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"BG009","title":"Phase 2: Cohort 1; FT-2102 (Single Agent)"},{"description":"Participants with AML in morphologic CR/CRi after prior therapy with residual IDH1-R132 mutation were received single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"BG010","title":"Phase 2: Cohort 2; FT-2102 (Single Agent)"},{"description":"Participants with R/R AML or MDS who were previously treated with FT-2102 and who underwent HSCT on-study then relapsed post-HSCT received single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"BG011","title":"Phase 2: Cohort 3; FT-2102 (Single Agent)"},{"description":"Participants with R/R AML that is naïve to prior hypomethylating therapy and IDH1 inhibitor therapy received combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"BG012","title":"Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants with R/R AML/MDS that have inadequately responded to or have progressed on prior hypo-methylating therapy received combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"BG013","title":"Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants with R/R AML/MDS that have been previously treated with single agent FT-2102 as their last therapy prior to study enrolment received combination therapy of azacitidine + FT-2102 150 mg BID in continuous 28-day cycles. Participants from the FT-2102 single agent cohorts of this study allowed to be enrolled in Cohort 6 after their disease progression.","id":"BG014","title":"Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants who have not received any prior AML treatment but may have received a prior treatment for another hematologic malignancy be given single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"BG015","title":"Phase 2: Cohort 7; FT-2102 (Single Agent)"},{"description":"Participants who have not received any prior AML treatment but may have received a prior treatment for another hematologic malignancy be given combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"BG016","title":"Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Total of all reporting groups","id":"BG017","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"10"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"37"},{"groupId":"BG010","value":"5"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"16"},{"groupId":"BG013","value":"3"},{"groupId":"BG014","value":"3"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"89"}],"title":"<65 years"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"14"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"68"},{"groupId":"BG010","value":"11"},{"groupId":"BG011","value":"3"},{"groupId":"BG012","value":"2"},{"groupId":"BG013","value":"9"},{"groupId":"BG014","value":"9"},{"groupId":"BG015","value":"3"},{"groupId":"BG016","value":"6"},{"groupId":"BG017","value":"144"}],"title":"65 - <75 years"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"7"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"48"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"2"},{"groupId":"BG013","value":"9"},{"groupId":"BG014","value":"8"},{"groupId":"BG015","value":"7"},{"groupId":"BG016","value":"4"},{"groupId":"BG017","value":"103"}],"title":">=75 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"14"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"74"},{"groupId":"BG010","value":"6"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"11"},{"groupId":"BG013","value":"7"},{"groupId":"BG014","value":"10"},{"groupId":"BG015","value":"6"},{"groupId":"BG016","value":"2"},{"groupId":"BG017","value":"158"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"17"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"79"},{"groupId":"BG010","value":"12"},{"groupId":"BG011","value":"3"},{"groupId":"BG012","value":"9"},{"groupId":"BG013","value":"14"},{"groupId":"BG014","value":"10"},{"groupId":"BG015","value":"4"},{"groupId":"BG016","value":"9"},{"groupId":"BG017","value":"178"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"5"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"10"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"5"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"2"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"15"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"19"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"71"},{"groupId":"BG010","value":"10"},{"groupId":"BG011","value":"4"},{"groupId":"BG012","value":"11"},{"groupId":"BG013","value":"14"},{"groupId":"BG014","value":"13"},{"groupId":"BG015","value":"5"},{"groupId":"BG016","value":"6"},{"groupId":"BG017","value":"191"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"16"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"2"},{"groupId":"BG017","value":"21"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"7"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"56"},{"groupId":"BG010","value":"7"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"8"},{"groupId":"BG013","value":"4"},{"groupId":"BG014","value":"7"},{"groupId":"BG015","value":"5"},{"groupId":"BG016","value":"3"},{"groupId":"BG017","value":"99"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"Full Analysis Set (FAS) included all the participants who were enrolled in the study and have received at least one dose of FT-2102."}